NNIT Valuation

Is NNIT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NNIT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NNIT (DKK91) is trading below our estimate of fair value (DKK296.89)

Significantly Below Fair Value: NNIT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NNIT?

Key metric: As NNIT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NNIT. This is calculated by dividing NNIT's market cap by their current earnings.
What is NNIT's PE Ratio?
PE Ratio	31x
Earnings	DKK 73.00m
Market Cap	DKK 2.26b

NNIT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	19.5x
PEG Ratio	0.6x

Price to Earnings Ratio vs Peers

How does NNIT's PE Ratio compare to its peers?

The above table shows the PE ratio for NNIT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	65.5x
4820 EM Systems	22.7x	8.9%	JP¥49.0b
000638 Vanfund Urban Investment and Development	83.7x	n/a	CN¥1.7b
2361 Sinohealth Holdings	17.9x	9.9%	HK$1.8b
300550 Heren HealthLtd	137.8x	n/a	CN¥3.7b
NNIT NNIT	31x	47.8%	DKK 2.3b

Price-To-Earnings vs Peers: NNIT is good value based on its Price-To-Earnings Ratio (31x) compared to the peer average (65.5x).

Price to Earnings Ratio vs Industry

How does NNIT's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NNIT is expensive based on its Price-To-Earnings Ratio (31x) compared to the European Healthcare Services industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is NNIT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NNIT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	31x
Fair PE Ratio	45.5x

Price-To-Earnings vs Fair Ratio: NNIT is good value based on its Price-To-Earnings Ratio (31x) compared to the estimated Fair Price-To-Earnings Ratio (45.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NNIT forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 91.00	DKK 122.50 +34.6%	14.3%	DKK 140.00	DKK 105.00	n/a	2
Nov ’25	DKK 103.40	DKK 142.50 +37.8%	5.3%	DKK 150.00	DKK 135.00	n/a	2
Oct ’25	DKK 125.00	DKK 142.50 +14.0%	5.3%	DKK 150.00	DKK 135.00	n/a	2
Sep ’25	DKK 107.60	DKK 142.50 +32.4%	5.3%	DKK 150.00	DKK 135.00	n/a	2
Aug ’25	DKK 106.60	DKK 137.50 +29.0%	1.8%	DKK 140.00	DKK 135.00	n/a	2
Jul ’25	DKK 106.00	DKK 137.50 +29.7%	1.8%	DKK 140.00	DKK 135.00	n/a	2
Jun ’25	DKK 108.00	DKK 137.50 +27.3%	1.8%	DKK 140.00	DKK 135.00	n/a	2
May ’25	DKK 107.20	DKK 137.50 +28.3%	1.8%	DKK 140.00	DKK 135.00	n/a	2
Apr ’25	DKK 108.20	DKK 105.00 -3.0%	33.3%	DKK 140.00	DKK 70.00	n/a	2
Mar ’25	DKK 103.80	DKK 105.00 +1.2%	33.3%	DKK 140.00	DKK 70.00	n/a	2
Feb ’25	DKK 97.00	DKK 95.00 -2.1%	26.3%	DKK 120.00	DKK 70.00	n/a	2
Jan ’25	DKK 84.10	DKK 95.00 +13.0%	26.3%	DKK 120.00	DKK 70.00	n/a	2
Dec ’24	DKK 86.00	DKK 95.00 +10.5%	26.3%	DKK 120.00	DKK 70.00	n/a	2
Nov ’24	DKK 80.20	DKK 95.00 +18.5%	26.3%	DKK 120.00	DKK 70.00	DKK 103.40	2
Oct ’24	DKK 85.00	DKK 95.00 +11.8%	26.3%	DKK 120.00	DKK 70.00	DKK 125.00	2
Sep ’24	DKK 83.80	DKK 95.00 +13.4%	26.3%	DKK 120.00	DKK 70.00	DKK 107.60	2
Aug ’24	DKK 81.80	DKK 95.00 +16.1%	26.3%	DKK 120.00	DKK 70.00	DKK 106.60	2
Jul ’24	DKK 79.70	DKK 95.00 +19.2%	26.3%	DKK 120.00	DKK 70.00	DKK 106.00	2
Jun ’24	DKK 84.70	DKK 95.00 +12.2%	26.3%	DKK 120.00	DKK 70.00	DKK 108.00	2
May ’24	DKK 75.40	DKK 95.00 +26.0%	26.3%	DKK 120.00	DKK 70.00	DKK 107.20	2
Apr ’24	DKK 69.30	DKK 95.00 +37.1%	26.3%	DKK 120.00	DKK 70.00	DKK 108.20	2
Mar ’24	DKK 70.00	DKK 90.00 +28.6%	33.3%	DKK 120.00	DKK 60.00	DKK 103.80	2
Feb ’24	DKK 69.90	DKK 90.00 +28.8%	33.3%	DKK 120.00	DKK 60.00	DKK 97.00	2
Jan ’24	DKK 65.70	DKK 90.00 +37.0%	33.3%	DKK 120.00	DKK 60.00	DKK 84.10	2
Dec ’23	DKK 64.60	DKK 90.00 +39.3%	33.3%	DKK 120.00	DKK 60.00	DKK 86.00	2
Nov ’23	DKK 56.00	DKK 90.00 +60.7%	33.3%	DKK 120.00	DKK 60.00	DKK 80.20	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.